Your Web News in One Place
November 8, 2019 04:45 pm

Ambrosia, the Young Blood Transfusion Startup, Is Quietly Back in Business

Earlier this year, Ambrosia, the much-maligned California startup selling blood transfusions from young donors, stopped offering the procedure after the U.S. Food and Drug Administration issued a buyer beware, warning consumers against using the service. But now, according to Ambrosia's CEO, the company is back up and running. From a report: Jesse Karmazin, the CEO and founder of Ambrosia, told OneZero in an interview that the company had resumed giving customers transfusions of plasma, the colorless liquid part of the blood, from young donors about a month ago. "Our patients really want the treatment," he said. "Patients are receiving plasma transfusions from donors ages 16 to 25 again." One-liter transfusions cost $8,000, and two-liter transfusions are $12,000. In a pitch about Ambrosia at a 2017 conference on self-enhancement, Karmazin said, "We're a company interested in making you young again." Plasma contains proteins that help the blood clot, and transfusions are often performed on patients to manage excessive bleeding, such as in trauma cases, and to treat clotting disorders like hemophilia. But experts say there's no basis for using plasma to slow or reverse aging or age-related diseases, like Karmazin has claimed. Critics have blasted Karmazin's transfusions as snake oil.

Read more of this story at Slashdot.

Original Link:

Share this article:    Share on Facebook
View Full Article


Slashdot was originally created in September of 1997 by Rob "CmdrTaco" Malda. Today it is owned by Geeknet, Inc..

More About this Source Visit Slashdot